# Mechanisms of Immune Reconstitution & Reduced Immune Activation Following Darunavir-based ART

> **NCT01869634** · PHASE4 · COMPLETED · sponsor: **University of California, Davis** · enrollment: 37 (actual)

## Conditions studied

- Human Immunodeficiency Virus Infection

## Interventions

- **DRUG:** darunavir with ritonavir and fixed-dose viread+emtricitabine daily

## Key facts

- **NCT ID:** NCT01869634
- **Lead sponsor:** University of California, Davis
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-06
- **Primary completion:** 2016-12
- **Final completion:** 2016-12
- **Target enrollment:** 37 (ACTUAL)
- **Last updated:** 2020-03-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01869634

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01869634, "Mechanisms of Immune Reconstitution & Reduced Immune Activation Following Darunavir-based ART". Retrieved via AI Analytics 2026-07-04 from https://api.ai-analytics.org/clinical/NCT01869634. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*